CN116723841A - 对er阳性癌症具有选择性的抗癌化合物 - Google Patents

对er阳性癌症具有选择性的抗癌化合物 Download PDF

Info

Publication number
CN116723841A
CN116723841A CN202180086814.XA CN202180086814A CN116723841A CN 116723841 A CN116723841 A CN 116723841A CN 202180086814 A CN202180086814 A CN 202180086814A CN 116723841 A CN116723841 A CN 116723841A
Authority
CN
China
Prior art keywords
compound
erso
dfp
trifluoromethyl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086814.XA
Other languages
English (en)
Chinese (zh)
Inventor
保罗·J·赫根罗特
马修·布德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN116723841A publication Critical patent/CN116723841A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180086814.XA 2020-10-23 2021-10-21 对er阳性癌症具有选择性的抗癌化合物 Pending CN116723841A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104933P 2020-10-23 2020-10-23
US63/104,933 2020-10-23
PCT/US2021/056003 WO2022087234A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Publications (1)

Publication Number Publication Date
CN116723841A true CN116723841A (zh) 2023-09-08

Family

ID=81290080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086814.XA Pending CN116723841A (zh) 2020-10-23 2021-10-21 对er阳性癌症具有选择性的抗癌化合物

Country Status (9)

Country Link
US (1) US12655104B2 (enExample)
EP (1) EP4232038A4 (enExample)
JP (1) JP2023546584A (enExample)
CN (1) CN116723841A (enExample)
AU (2) AU2021366688B2 (enExample)
CA (1) CA3196210A1 (enExample)
IL (1) IL302154A (enExample)
MX (1) MX2023004480A (enExample)
WO (1) WO2022087234A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途
WO2026039467A1 (en) * 2024-08-12 2026-02-19 The Board Of Trustees Of The University Of Illinois Hydroxyphenyl-indoline-2-one cancer therapeutics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2008129075A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
CN105102452A (zh) * 2013-04-26 2015-11-25 百济神州有限公司 取代的5-(3,5-二甲基异噁唑-4-基)二氢吲哚-2-酮类衍生物
CN108440378A (zh) * 2018-03-27 2018-08-24 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法
WO2020009958A1 (en) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2855406A (en) 1955-05-07 1958-10-07 Dann Otto Preparation of benzopyrans and benzofurans
US3773759A (en) 1972-08-21 1973-11-20 Searle & Co 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2008129075A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
CN105102452A (zh) * 2013-04-26 2015-11-25 百济神州有限公司 取代的5-(3,5-二甲基异噁唑-4-基)二氢吲哚-2-酮类衍生物
CN108440378A (zh) * 2018-03-27 2018-08-24 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法
WO2020009958A1 (en) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
CN112423743A (zh) * 2018-07-03 2021-02-26 伊利诺伊大学评议会 未折叠蛋白反应的激活剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
METTE K. CHRISTENSEN等: "Synthesis and Antitumor Effect in Vitro and in Vivo of Substituted 1, 3-Dihydroindole-2-ones", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 53, no. 19, 31 December 2010 (2010-12-31), pages 7140 - 7145, XP055574364, DOI: 10.1021/jm100763j *
SHIYAO LIU等: "Chiral Tertiary Sulfonium Salts as Effective Catalysts for Asymmetric Base-Free Neutral Phase-Transfer Reactions", 《ANGEW. CHEM. 》, 31 December 2017 (2017-12-31), pages 4897 - 4901 *
XIN LI等: "Chiral Amine Thiourea-Promoted Enantioselective Michael Addition Reactions of 3-Substituted Benzofuran-2(3H)-ones to Maleimides", 《J. ORG. CHEM》, vol. 75, 24 November 2010 (2010-11-24), pages 8697 *

Also Published As

Publication number Publication date
AU2021366688A9 (en) 2024-06-20
MX2023004480A (es) 2023-05-04
US12655104B2 (en) 2026-06-16
EP4232038A4 (en) 2024-04-10
IL302154A (en) 2023-06-01
AU2021366688A1 (en) 2023-05-25
JP2023546584A (ja) 2023-11-06
EP4232038A1 (en) 2023-08-30
AU2026204244A1 (en) 2026-06-18
CA3196210A1 (en) 2022-04-28
WO2022087234A1 (en) 2022-04-28
US20230391721A1 (en) 2023-12-07
AU2021366688B2 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
CN113853379B (zh) 含氟化合物及抗癌医药用途
CN108366996B (zh) 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
TWI837402B (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
US8394794B2 (en) Therapeutic compounds
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
JP5694172B2 (ja) カルバゾール化合物および当該化合物の治療用途
JP2022513959A5 (enExample)
JP2024512544A (ja) テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
EP4137483A1 (en) Benzonitric heterocyclic compound, preparation method therefor and use thereof
JP2021185193A (ja) インデニル化合物、医薬組成物、およびその医学的使用
WO2025108255A1 (zh) 一种多环类衍生物、其制备方法和应用
CA3103958A1 (en) Activators of the unfolded protein response
CA2771234A1 (en) Substituted hydrazide compounds and use thereof
AU2021366688B2 (en) Anticancer compounds selective for er-positive cancers
CA2859992A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
WO2014127722A1 (zh) 氮杂环取代二氢青蒿素衍生物及其应用
JP5341521B2 (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
WO2020263822A1 (en) Selective btk irreversible inhibitors
KR20210134306A (ko) 아크릴-함유 핵 수출 조절제들 및 이들의 용도들
WO2021189051A1 (en) Androgen receptor regulation by small molecule enantiomers
CN117603219A (zh) 一种p-糖蛋白抑制剂及其制备方法和应用
TWI267511B (en) Process for preparing 10,11-methanobenzosuberane derivatives
US12552806B2 (en) Androgen receptor regulation by small molecule enantiomers
US20250376477A1 (en) Analgesic delta opioid receptor bitopic ligands
WO2026039467A1 (en) Hydroxyphenyl-indoline-2-one cancer therapeutics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination